Opexa Therapeutics, Inc. (OPXA) is a publicly traded company in the Unknown sector. Across all available filings, 13 corporate insiders have executed 108 transactions totaling $1.6M, demonstrating a bearish sentiment with -$726.2K in net insider flow. The most recent transaction on Nov 18, 2016 involved a sale of 7,105 shares valued at $3.9K.
No significant insider buying has been recorded for OPXA in the recent period.
No significant insider selling has been recorded for OPXA in the recent period.
Based on recent SEC filings, insider sentiment for OPXA is bearish with an Insider Alignment Score of 27/100 and a net flow of -$726.2K. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Opexa Therapeutics, Inc. (OPXA) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 13 insiders are actively trading OPXA stock, having executed 108 transactions in the past 90 days. The most active insider is Austin W. &. Greenhouse David M. Marxe (Executive), who has made 17 transactions totaling $916.6K.
Get notified when executives and directors at OPXA file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Nov 18, 2016 | C. Barabe Timothy | Executive | Sale | 7,105 | $0.55 | $3.9K | |
| Nov 18, 2016 | C. Barabe Timothy | Executive | Sale | 7,809 | $0.55 | $4.3K | |
| Sep 30, 2016 | C. Barabe Timothy | Executive | Award | 6,455 | $N/A | $0 | |
| Sep 30, 2016 | J. Maderis Gail | Executive | Award | 6,455 | $N/A | $0 | |
| Sep 30, 2016 | Richman Michael | Executive | Award | 6,455 | $N/A | $0 | |
| Sep 30, 2016 | B. Seaman Scott | Executive | Award | 6,455 | $N/A | $0 | |
| Jun 30, 2016 | Richman Michael | Executive | Award | 6,455 | $N/A | $0 | |
| Jun 30, 2016 | B. Seaman Scott | Executive | Award | 6,455 | $N/A | $0 | |
| Jun 30, 2016 | C. Barabe Timothy | Executive | Award | 6,455 | $N/A | $0 | |
| Jun 30, 2016 | J. Maderis Gail | Executive | Award | 6,455 | $N/A | $0 | |
| May 16, 2016 | C. Barabe Timothy | Executive | Award | 6,455 | $N/A | $0 | |
| May 16, 2016 | J. Maderis Gail | Executive | Award | 6,455 | $N/A | $0 | |
| May 16, 2016 | B. Seaman Scott | Executive | Award | 6,455 | $N/A | $0 | |
| May 16, 2016 | Richman Michael | Executive | Award | 6,455 | $N/A | $0 | |
| Dec 31, 2015 | Richman Michael | Executive | Award | 1,354 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 29 | $1.2M | 43.9% |
Conversion(C) | 6 | $764.4K | 28.8% |
Purchase(P) | 19 | $440.6K | 16.6% |
Award(A) | 45 | $194.7K | 7.3% |
Exercise (Options)(X) | 1 | $76.0K | 2.9% |
Exercise(M) | 8 | $16.0K | 0.6% |
Insider selling pressure at Opexa Therapeutics, Inc. has increased, with 13 insiders executing 108 transactions across all time. Total sales of $1.2M significantly outpace purchases of $440.6K, resulting in a net outflow of $726.2K. This selling activity appears largely discretionary, which may warrant closer attention from investors.